Associate Professor and Director, Pharmaceutical Sciences Graduate Program
Department of Pharmaceutical Sciences
College of Pharmacy
University of Nebraska Medical Center
986125 Nebraska Medical Center
Omaha, NE 68198-6125
Dr. Trippier lectures in Medicinal Chemistry and Drug Discovery
Dr. Trippier’s research is focused on small molecule drug discovery for cancer and neurodegenerative diseases. His lab employs synthetic medicinal chemistry, chemical biology and molecular pharmacology techniques to design, optimize and employ biologically active compounds as chemical probes to interrogate novel pathways relevant to human disease and as lead compounds for novel drug discovery.
Discoveries in the Trippier lab have led to the identification of the most potent and selective Aldo-keto reductase 1C3 (AKR1C3) inhibitor which shows significant effect to counter drug resistance in prostate cancer and leukemia; the most potent synthetic succinate dehydrogenase inhibitor yet described with significant anticancer activity; novel multi-targeted agents for neurodegenerative disease therapy; and potent activators of neurolysin for stroke therapy development. This research has been and is currently funded by the NCI, NINDS, various private foundations and the pharmaceutical industry.
- Md. Shafikur Rahman, Shikha Kumari, Shiva H. Esfahani, Saeideh Nozohouri, Srinidhi Jayaraman, Nihar Kinarivala, Joanna Kocot, Andrew Baez, Delaney Farris, Thomas J. Abbruscato, Vardan T. Karamyan and Paul C. Trippier; Discovery of first-in-class peptidomimetic neurolysin activators possessing enhanced brain penetration and stability. J. Med. Chem. 2021, 64, 12705-12722.
- Trevor M. Penning, Sravan Jonnalagadda, Paul C. Trippier and Tea Lanisnik Rizner; Aldo-keto reductases and cancer drug resistance. Pharmacol. Rev. 2021, 73, 1150-1171.
- Bader I. Huwaimel, Myla Bhakta, Chaitanya A. Kulkarni, Alexander S. Milliken, Feifei Wang, Aimin Peng, Paul S. Brookes, and Paul C. Trippier; Discovery of halogenated benzothiadiazine derivatives with anticancer activity. ChemMedChem 2021, 16, 1143-1162.
- Shikha Kumari, Angelica V. Carmona, Amit K. Tiwari and Paul C. Trippier; Amide bond bioisosteres: Strategies, synthesis and successes. J. Med. Chem. 2020, 63, 12290-12358.
- Ahmed Morsy and Paul C. Trippier; Reversal of Apalutamide and Darolutamide aldo-keto reductase 1C3-mediated resistance by a small molecule inhibitor. ACS Chem. Biol. 2020, 15, 646-650.
- Nihar Kinarivala, Ahmed Morsy, Ronak Patel, Angelica V. Carmona, Md. Sanaullah Sajib, Snehal Raut, Constantinos M. Mikelis, Abraham J. Al-Ahmed, and Paul C. Trippier; An iPSC-derived neuron model of CLN3 disease facilitates small molecule phenotypic screening. ACS Pharmacol. Transl. Sci. 2020, 3, 931-947.
- Kshitij Verma, Tianzhu Zang, Trevor M. Penning, and Paul C. Trippier; Potent and highly selective aldo-keto reductase 1C3 (AKR1C3) inhibitors act as chemotherapeutic potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. J. Med. Chem. 2019, 62, 3590-3616.
- Ahmed Morsy and Paul C. Trippier; Amyloid-Binding Alcohol Dehydrogenase (ABAD) inhibitors for the treatment of Alzheimer’s disease. J. Med. Chem. 2019, 62, 4252-4264.
- Joelle Makoukji, Fadi Saadeh, Karl Albert Mansour, Sally El Sitt, Jamal Al Ali, Nihar Kinarivala, Paul C. Trippier and Rose-Mary Boustany; Flupirtine derivatives as potential treatment for the Neuronal Ceroid Lipofuscinoses. Ann. Clin. Transl. Neurol. 2018, 5, 1089-1103.
- Kshitij Verma, Nehal Gupta, Tianzhu Zang, Beau Wangtrakluldee, Sanjay K. Srivastava, Trevor M. Penning, and Paul C. Trippier; AKR1C3 inhibitor KV-37 exhibits antineoplastic effects and potentiates enzalutamide in combination therapy in prostate adenocarcinoma cells. Mol. Cancer Ther. 2018, 17,1833-1845.